Retinoblastoma-E2F1 signaling pathway (Rb-E2F pathway) (Rb-E2F pathway)

The Retinoblastoma (Rb)-E2F1 signaling pathway is a fundamental regulatory circuit that controls the G1 to S phase transition of the eukaryotic cell cycle [1, 11]. In its active, hypophosphorylated state, the Rb protein acts as a tumor suppressor by binding to E2F1 and related transcription factors, effectively silencing the expression of genes required for DNA synthesis and cell cycle progression [6, 12]. Mitogenic signals trigger the activation of Cyclin D-CDK4/6 complexes, which phosphorylate Rb, leading to the release of E2F1 and the subsequent initiation of the S-phase [1, 3]. Dysregulation of this pathway—often through RB1 gene loss, Cyclin D amplification, or p16INK4A inactivation—is a nearly universal feature of human malignancies, driving autonomous cellular proliferation [2, 4]. Pharmacological targeting of this pathway primarily involves CDK4/6 inhibitors, which restore the inhibitory function of Rb to induce senescence or apoptosis in cancer cells [3, 13]. The target name provided, "Rb–E2F-1 pathway–dysregulated cancer cells," refers to the cellular phenotype resulting from this dysregulation rather than a specific molecular target, though it is often used to describe the selectivity profile of oncolytic viruses and experimental E2F-targeted agents [1, 8].

Other names

Rb-E2F1 axisRetinoblastoma pathwayG1/S checkpoint pathwayRb-E2F-1 pathway-dysregulated cancer cells

Inhibition of Cyclin-dependent kinases 4 and 6 (CDK4/6) to prevent the phosphorylation of the Retinoblastoma (Rb) protein, thereby maintaining its association with E2F1 transcription factors and inducing G1-phase cell cycle arrest [1, 3].